Companies · Biotechnology

Cardiac Insight, Inc.

Bellevue · Biotechnology

Diligence memoA one-page analyst read on Cardiac Insight, Inc. — recommendation, valuation, rhythm, risks.
$38.1M
Total raised · real
13
Rounds
2.4×
Latest step-up
Top 23%
Sector rank · raised
Series A
Latest stage · inferred · Thu Mar 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Cardiac Insight, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 4.15× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
Dormant
  • Last raise 4.3 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Cardiac Insight, Inc. is one of 4293 Biotechnology companies tracked from Bellevue. By capital raised it ranks in the upper tier (ahead of 78% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
6
Investors (latest)
2022-03-17
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MPre-Seed · 2010-12-30 Raised $200K (real) Modeled valuation $11M (est)Pre-Seed2010Pre-Seed · 2011-09-26 Raised $315K (real) Modeled valuation $17M (est)Pre-Seed2011Pre-Seed · 2011-11-14 Raised $700K (real) Modeled valuation $39M (est)Pre-Seed2011Pre-Seed · 2012-09-11 Raised $285K (real) Modeled valuation $16M (est)Pre-Seed2012Seed · 2013-08-06 Raised $1.4M (real) Modeled valuation $60M (est)Seed2013Seed · 2014-01-14 Raised $2.0M (real) Modeled valuation $89M (est)Seed2014Series A · 2014-06-26 Raised $7.1M (real) Modeled valuation $256M (est)Series A2014Series A · 2015-09-08 Raised $3.5M (real) Modeled valuation $127M (est)Series A2015Series A · 2016-04-13 Raised $2.5M (real) Modeled valuation $91M (est)Series A2016Series A · 2016-11-22 Raised $1.0M (real) Modeled valuation $36M (est)Series A2016Series A · 2017-05-05 Raised $2.8M (real) Modeled valuation $103M (est)Series A2017Pre-Seed · 2017-05-05 Raised $175K (real) Modeled valuation $9.7M (est)Pre-Seed2017Series A · 2019-07-30 Raised $4.7M (real) Modeled valuation $172M (est)Series A2019Series A · 2022-03-17 Raised $12M (real) Modeled valuation $184M (est)Series A2022Cumulative $38M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$200K · 2010
Pre-Seed extension$315K · 2011
Pre-Seed extension$700K · 2011
Pre-Seed extension$285K · 2012
Seed$1.4M · 2013
Seed extension$2.0M · 2014
Series A$7.1M · 2014
Series A extension$3.5M · 2015
Series A extension$2.5M · 2016
Series A extension$1.0M · 2016
Series A extension$2.8M · 2017
Bridge · Series A-stage$175K · 2017smaller follow-on
Series A extension$4.7M · 2019
Series A extension$11.6M · 2022

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$184.0M
Base estimate est.
$12.7M
Conservative case
$675.2M
Upside case
$52.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $11.0M · 2010-12-302010Pre-Seed · modeled $17.4M · 2011-09-26Pre-Seed · modeled $38.6M · 2011-11-14Pre-Seed · modeled $15.7M · 2012-09-11Seed · modeled $60.1M · 2013-08-06Seed · modeled $88.8M · 2014-01-14Series A · modeled $255.6M · 2014-06-26Series A · modeled $126.5M · 2015-09-08Series A · modeled $90.6M · 2016-04-13Series A · modeled $36.2M · 2016-11-22Series A · modeled $102.5M · 2017-05-05Pre-Seed · modeled $9.7M · 2017-05-05Series A · modeled $171.6M · 2019-07-30Series A · modeled $184.0M · 2022-03-172022
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
4.3 yr
Elapsed time used
4.3 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
10 mo
Avg between rounds
$3.4M/yr
Capital velocity
15.5 yr
On record since
2010
First round
14
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 5.3× above median
This company$38.1M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 2.1× above median
This company$11.6M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 2.9× above median
This company$184.0M
Sector median$64.2M

Raised more than 78% of sector peers (real $). Modeled value above 71% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #8 of 303.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)GeoVax Labs, Inc. · Series A Raised $39.1M · modeled $217.3M (est)Cellinfinity Bio Holding Company, LLC · Series A Raised $13.2M · modeled $216.2M (est)Adient Medical, Inc. · Series A Raised $18.2M · modeled $207.1M (est)Entegrion Inc · Series A Raised $22.7M · modeled $191.5M (est)BCD Bioscience, Inc. · Series A Raised $16.4M · modeled $189.2M (est)Pragma Biosciences Inc. · Series A Raised $14.5M · modeled $186.2M (est)MicroByre, Inc. · Series A Raised $16.1M · modeled $185.9M (est)Cardiac Implants LLC · Series A Raised $13.5M · modeled $178.4M (est)Abintus Bio, Inc. · Series A Raised $13.7M · modeled $177.4M (est)Mosaic Biosciences, Inc. · Series A Raised $14.7M · modeled $176.4M (est)Mazen Animal Health Inc. · Series A Raised $13.5M · modeled $169.0M (est)Cardiac Insight, Inc. (this company) Raised $38.1M · modeled $184.0M (est)Cardiac Insight, Inc.
CompanyStageRaised · realValue · estvs peer med.
GeoVax Labs, Inc.Series A$39.1M$217.3M4.90×
Cellinfinity Bio Holding Company, LLCSeries A$13.2M$216.2M4.87×
Adient Medical, Inc.Series A$18.2M$207.1M4.67×
Entegrion IncSeries A$22.7M$191.5M4.32×
BCD Bioscience, Inc.Series A$16.4M$189.2M4.27×
Pragma Biosciences Inc.Series A$14.5M$186.2M4.20×
MicroByre, Inc.Series A$16.1M$185.9M4.19×
Cardiac Insight, Inc. this companySeries A$38.1M$184.0M4.15×
Cardiac Implants LLCSeries A$13.5M$178.4M4.02×
Abintus Bio, Inc.Series A$13.7M$177.4M4.00×
Mosaic Biosciences, Inc.Series A$14.7M$176.4M3.98×
Mazen Animal Health Inc.Series A$13.5M$169.0M3.81×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$200K2010-12-30$1.1M$11.0M85%
Pre-Seed$315K2011-09-26$1.8M$17.4M85%
Pre-Seed$700K2011-11-14$3.9M$38.6M85%
Pre-Seed$285K2012-09-11$1.6M$15.7M85%
Seed$1.4M2013-08-06$6.8M$60.1M85%
Seed$2.0M2014-01-14$10.0M$88.8M85%
Series A$7.1M2014-06-26$32.1M$255.6M85%
Series A$3.5M2015-09-08$15.9M$126.5M85%
Series A$2.5M2016-04-13$11.4M$90.6M85%
Series A$1.0M2016-11-22$4.5M$36.2M90%
Series A$2.8M2017-05-05$12.9M$102.5M90%
Pre-Seed$175K2017-05-05$972K$9.7M90%
Series A$4.7M2019-07-30$21.6M$171.6M90%
Series A$11.6M2022-03-17$52.7M$184.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$200K2010-12-30
    • First recorded raise — entered as Pre-Seed.
    • 4 investors on this round.
  2. Pre-Seed$315K2011-09-26
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round 1.6× larger than the prior — scaling up.
    • 12 investors on this round.
  3. Pre-Seed$700K2011-11-14
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 2.2× larger than the prior — scaling up.
    • 17 investors on this round.
  4. Pre-Seed$285K2012-09-11
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round 2.5× smaller than the prior — bridge or down round.
    • 13 investors on this round.
  5. Seed$1.4M2013-08-06
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round 4.8× larger than the prior — scaling up.
    • 29 investors on this round.
  6. Seed$2.0M2014-01-14
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 1.5× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 1 investor on this round.
  7. Series A$7.1M2014-06-26
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 3.5× larger than the prior — scaling up.
    • 2 investors on this round.
  8. Series A$3.5M2015-09-08
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 2 investors on this round.
  9. Series A$2.5M2016-04-13
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round 1.4× smaller than the prior — bridge or down round.
    • 30 investors on this round.
  10. Series A$1.0M2016-11-22
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round 2.5× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  11. Series A$2.8M2017-05-05
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 2.8× larger than the prior — scaling up.
    • 31 investors on this round.
  12. Pre-Seed$175K2017-05-05
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 16.2× smaller than the prior — bridge or down round.
    • 6 investors on this round.
  13. Series A$4.7M2019-07-30
    • Raised again after 27 mo — slower than the ~14 mo sector norm.
    • Round 27.1× larger than the prior — scaling up.
    • 12 investors on this round.
  14. Series A$11.6M2022-03-17
    • Raised again after 32 mo — slower than the ~14 mo sector norm.
    • Round 2.4× larger than the prior — scaling up.
    • 6 investors on this round.
Intelligence
2023 ~Q1
Modeled next raise · ~10mo cadence
$28.4M
Modeled next size est.range $18.4M$45.4M
2.4×
Last step-up
$3.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Clifford Stocks4 other2019-07
Brad Harlow3 other2011-09
Bill Willis2 other2013-08
Richard O Martin2 other2010-12
Robert Odell2 other2022-03
Michael Schuh1 other2022-03
Richard Martin1 other2011-09
Robert Hauser1 other2011-09
Ann Demaree2022-03
Bob Odell2014-01
Brad T Harlow2010-12
Daniel Tylutki2022-03
David Hadley2022-03
David Linker2011-09
David T Linker2010-12
Hemanth Reddy2015-09
Hyoung Min Kim2022-03
Kirby Cramer2011-09
Kirby L Cramer2010-12
Kurt Noltensmeyer2022-03
Lex Gamble2011-11
Mike Schuh2014-01
Robert deGavre2011-09
Robert G Hauser2010-12
Registry & provenance

Cardiac Insight, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1509098
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Theraclone Sciences, Inc.BiotechnologySeries A$36.7M$111.3Mnetwork1 shared operator · same sector · same stage
Entegrion IncBiotechnologySeries A$22.7M$191.5Mnetwork1 shared operator · same sector · same stage
Yor Labs, Inc.BiotechnologySeries B$37.7M$167.2Mnetwork1 shared operator · same sector
K2 Biolabs, Inc.BiotechnologySeries A$6.1M$5.4Mnetwork1 shared operator · same sector · same stage
Prescient Medical IncBiotechnologySeries A$5.2M$187.1Mnetwork1 shared operator · same sector · same stage
GeoVax Labs, Inc.BiotechnologySeries A$39.1M$217.3Msame sector · same stage
ImmunoGenesis, Inc.BiotechnologySeries C$50.2M$43.0Mnetwork1 shared operator · same sector
Augmenix IncBiotechnologySeries A$40.6M$216.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Second Heart Assist, Inc.BiotechnologySeries B$39.7M90%
CardioFocus, Inc.BiotechnologySeries B$352.4M90%
Innovative Cardiovascular Solutions, LLCBiotechnologySeed$13.0M90%
Genome Insight, Inc.BiotechnologySeries A$39.9M90%
Heartflow, Inc.BiotechnologySeries D+$2.7B89%
Cardiac Implants LLCBiotechnologySeries A$178.4M89%
Cardio Flow, Inc.BiotechnologySeries A$2.1M89%
Native Cardio, Inc.BiotechnologySeed$506K88%
Frequently asked
How much funding has Cardiac Insight, Inc. raised?
Cardiac Insight, Inc. has raised approximately $38.1M in disclosed capital across 13 recorded financing rounds, aggregated from public filings.
What is Cardiac Insight, Inc.'s estimated valuation?
Provath's modeled valuation for Cardiac Insight, Inc. is approximately $184.0M (modeled range $12.7M–$675.2M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Cardiac Insight, Inc. at?
Cardiac Insight, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Thu Mar 17.
What does Cardiac Insight, Inc. do and where is it based?
Cardiac Insight, Inc. operates in the Biotechnology sector, based in Bellevue.
Explore related

See where Cardiac Insight, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Cardiac Insight, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.